Advertisement

Topics

Argos Surges on Positive Phase III Kidney Cancer Data

19:00 EST 12 Nov 2017 | BioSpace

A total of 462 patients were enrolled in the ADAPT study and randomized 2:1 between combination treatment with Rocapuldencel-T and sunitinib (combination arm) vs. sunitinib monotherapy (control arm).

Original Article: Argos Surges on Positive Phase III Kidney Cancer Data

NEXT ARTICLE

More From BioPortfolio on "Argos Surges on Positive Phase III Kidney Cancer Data"

Advertisement
Quick Search
Advertisement
Advertisement